LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2024.
Fourth Quarter Fiscal 2024 Summary*:
Revenue of $48.9 million, a decrease of 9.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, fourth quarter revenue was down approximately 8.0%;
Revenue in the Americas decreased 4.1% and revenue in Asia/Pacific & Europe decreased 25.2%.
Excluding the negative impact of foreign currency fluctuations, fourth quarter revenue in Asia/Pacific & Europe decreased 18.6%;
Net income per diluted share was $0.10, versus $0.15 per diluted share a year ago;
Adjusted earnings per diluted share were $0.14, compared to $0.17 a year ago; and
Adjusted EBITDA of $4.8 million was flat compared to a year ago.
*All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2024 to the fourth quarter of fiscal 2023, unless otherwise noted.
Fiscal Year 2024 Summary**:
Revenue of $200.2 million, a decrease of 6.2%.
Excluding the negative impact of foreign currency fluctuations, fiscal year 2024 revenue was down approximately 5.2%;
Revenue in the Americas decreased 1.6%, and revenue in Asia/Pacific & Europe decreased 18.6%.
Excluding